ArticleIJID regions2026
Human granulocytic anaplasmosis in Poland: clinical déjà vu or a new chapter in tick-borne diseases?
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tick-borne diseases represent an increasing public health concern worldwide, including human granulocytic anaplasmosis (HGA). HGA is gaining relevance in travel medicine due to its expanding geographic distribution. Its true incidence remains unknown, largely due to underreporting and diagnostic challenges. HGA manifests itself by nonspecific symptoms and may be misdiagnosed as another tick-borne disease. This study aimed to direct focus on clinical manifestations of this disease and to examine the role of co-infection with other tick-borne pathogens on its clinical manifestations and laboratory results. An additional aim was to compare the obtained results with previous analysis performed on 120 patients. Methods: A retrospective clinical evaluation was conducted for all patients based on data extracted from their medical records. Each patient was assessed by the same team of physicians with extensive expertise in tick-borne diseases. The clinical assessment included a detailed history focused on key epidemiological and exposure-related factors. Patients had laboratory tests performed and all of them also had polymerase chain reaction tests to confirm infection. Overall, 22 patients with anaplasmosis were qualified. Results: This study presents symptoms that can differentiate patients with HGA mono-infection and co-infected group with significantly elevated aspartate aminotransferase observed in the mono-infection group. Conclusion: Including anaplasmosis in the differential diagnosis is essential in travel medicine, particularly in febrile patients with cytopenias following travel to endemic or rural areas. A thorough diagnostic approach-integrating epidemiological history, clinical manifestations (such as fever, cytopenias, transaminase elevation, especially elevated aspartate aminotransferase levels after excluding non-infectious causes), targeted laboratory investigations, and confirmatory polymerase chain reaction testing-is critical for timely and accurate identification of HGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.